INTRODUCTION According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce the daily use of the L-dopa dosage requirements and it can also reduce the side effects which are associated with the L...

Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic ...

-The DOPA-decarboxylase (aromatic-L-amino acid decarboxylase) inhibitors benserazide, its active metabolite 2,3,4-trihydroxybenzylhydrazine and carbidopa are substrates of highly purified catechol-O-methyltransferase. The affinity and maximal velocity of both benserazide and trihydroxybenzyl hydrazine are extremely favourable implying that these compounds may compete as substrates for catechol-...

IPX066 (extended-release carbidopa-levodopa [ER CD-LD]) is an oral extended-release capsule formulation of carbidopa and levodopa. The single-dose pharmacokinetics of ER CD-LD (as 2 capsules; total dose, 97.5 mg-390 mg CD-LD) versus immediate-release (IR) CD-LD (25 mg-100 mg), sustained-release (CR) CD-LD (25 mg-100 mg), and CD-LD-entacapone (25 mg-100 mg-200 mg) was evaluated in healthy subjec...

Abstract: Background: Parkinson’s disease is neurodegenerative with no cure till now, there are treatments that can be explored to ease the symptoms of this disease, and using plant extract we explore possibility neutralizing adverse providing better quality life patients. Purpose: To demonstrate Anti-parkinson’s activity Phaseolus vulgaris methanol pod by behavioural models in Wister Albino ra...

La enfermedad de Parkinson (EP) se puede considerar como la segunda neurodegenerativa en cuanto a prevalencia refiere. EP es una carácter crónico que evoluciona fases consecutivas, con un diagnóstico inicial insidioso y manejo complejo para el médico Atención Primaria. En este artículo presentamos caso interacción medicamentosa poco estudiada entre fármacos antidepresivos antiparkinsonianos. pa...

Sensory symptoms related to pain perception have been reported to occur in 30-50% of parkinsonian patients. Two patients with Parkinson's disease are reported, in whom painful sensory phenomena preceded or accompanied the disease process. In both patients the sensory phenomena were unresponsive to therapy with oral narcotics, anti-inflammatory drugs or administration of levodopa/carbidopa. Benz...